– Manuscript highlights development of robust responses to both influenza and COVID-19 and protection against the SARS-CoV-2 virus – Data shared via preprint server for biology, bioRxiv, ahead of publication Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced data from a preclinical study of the company’s combination quadrivalent seasonal…